Need help choosing the right code?
Ask CasePilot about procedures, modifiers, bundling, and coding guidance.
Try CasePilot© Copyright 2026 American Medical Association. All rights reserved.
The CPT® Code 82232 refers to a laboratory test specifically designed to measure the levels of beta-2 microglobulin (B2M) in various biological samples. Beta-2 microglobulin is a small protein that is present on the surface of certain cells, including B lymphocytes, which are a type of white blood cell, as well as tumor cells. This protein can shed into the bloodstream and may also be detected in urine and cerebrospinal fluid (CSF). While B2M testing is not classified as a differential test, it serves a significant role in providing additional clinical insights regarding the progression of various diseases. The test is particularly relevant for patients diagnosed with conditions such as multiple myeloma, lymphoma, multiple sclerosis, liver and kidney diseases, chronic inflammatory disorders, HIV/AIDS, and cytomegalovirus (CMV) infections. The collection of samples for B2M testing involves obtaining a blood sample through a separately reportable venipuncture, a CSF sample via a separately reportable lumbar puncture, and a urine sample which can be collected either as a voided specimen or through catheterization. For urine collection, it is important to discard the first specimen, ensure the patient is hydrated by providing water, and then collect a second urine sample within one hour for accurate analysis. The testing methodologies employed for serum/plasma and CSF samples include quantitative immunoturbidimetry, while urine samples are analyzed using a quantitative chemiluminescent immunoassay.
© Copyright 2026 Coding Ahead. All rights reserved.
The beta-2 microglobulin (B2M) test is indicated for use in various clinical scenarios, particularly for monitoring disease progression and assessing the severity of certain medical conditions. The following are the specific indications for which this test may be performed:
The procedure for obtaining samples for beta-2 microglobulin (B2M) testing involves several distinct steps, each critical for ensuring accurate results. The first step is the collection of a blood sample, which is performed through a separately reportable venipuncture. This involves inserting a needle into a vein, typically in the arm, to draw blood for analysis. Following the blood collection, a cerebrospinal fluid (CSF) sample may be obtained through a separately reportable lumbar puncture. This procedure requires careful technique to insert a needle into the lower back to access the CSF surrounding the spinal cord. Additionally, a urine sample is required for B2M testing, which can be collected either as a voided specimen or through catheterization. For the urine collection, it is essential to discard the first urine specimen to avoid contamination. The patient should be encouraged to drink water to ensure adequate hydration, and a second urine sample should be collected within one hour for analysis. The testing methodologies employed for the collected samples include quantitative immunoturbidimetry for serum/plasma and CSF samples, while urine samples are analyzed using a quantitative chemiluminescent immunoassay. These methods are designed to accurately quantify the levels of beta-2 microglobulin present in the samples.
After the collection of samples for beta-2 microglobulin testing, there are no specific post-procedure care requirements mentioned in the provided data. However, it is generally advisable for patients to remain hydrated, especially after urine collection, to facilitate accurate testing. The results of the B2M test will be analyzed and reported, providing valuable information regarding the patient's condition and aiding in the management of their health. It is important for healthcare providers to interpret the results in conjunction with other clinical findings and diagnostic tests to ensure comprehensive patient care.
| Short Descr | ASSAY OF BETA-2 PROTEIN | Medium Descr | BETA-2 MICROGLOBULIN | Long Descr | Beta-2 microglobulin | Status Code | Statutory Exclusion (from MPFS, may be paid under other methodologies) | Global Days | XXX - Global Concept Does Not Apply | PC/TC Indicator (26, TC) | 9 - Not Applicable | Multiple Procedures (51) | 9 - Concept does not apply. | Bilateral Surgery (50) | 9 - Concept does not apply. | Physician Supervisions | 09 - Concept does not apply. | Assistant Surgeon (80, 82) | 9 - Concept does not apply. | Co-Surgeons (62) | 9 - Concept does not apply. | Team Surgery (66) | 9 - Concept does not apply. | Diagnostic Imaging Family | 99 - Concept Does Not Apply | CLIA Waived (QW) | No | APC Status Indicator | Conditionally packaged laboratory tests | Type of Service (TOS) | 5 - Diagnostic Laboratory | Berenson-Eggers TOS (BETOS) | T1H - Lab tests - other (non-Medicare fee schedule) | MUE | 2 | CCS Clinical Classification | 235 - Other Laboratory |
| 90 | Reference (outside) laboratory: when laboratory procedures are performed by a party other than the treating or reporting physician or other qualified health care professional, the procedure may be identified by adding modifier 90 to the usual procedure number. | Q1 | Routine clinical service provided in a clinical research study that is in an approved clinical research study | Q4 | Service for ordering/referring physician qualifies as a service exemption | 91 | Repeat clinical diagnostic laboratory test: in the course of treatment of the patient, it may be necessary to repeat the same laboratory test on the same day to obtain subsequent (multiple) test results. under these circumstances, the laboratory test performed can be identified by its usual procedure number and the addition of modifier 91. note: this modifier may not be used when tests are rerun to confirm initial results; due to testing problems with specimens or equipment; or for any other reason when a normal, one-time, reportable result is all that is required. this modifier may not be used when other code(s) describe a series of test results (eg, glucose tolerance tests, evocative/suppression testing). this modifier may only be used for laboratory test(s) performed more than once on the same day on the same patient. | GA | Waiver of liability statement issued as required by payer policy, individual case | GZ | Item or service expected to be denied as not reasonable and necessary | 26 | Professional component: certain procedures are a combination of a physician or other qualified health care professional component and a technical component. when the physician or other qualified health care professional component is reported separately, the service may be identified by adding modifier 26 to the usual procedure number. | 59 | Distinct procedural service: under certain circumstances, it may be necessary to indicate that a procedure or service was distinct or independent from other non-e/m services performed on the same day. modifier 59 is used to identify procedures/services, other than e/m services, that are not normally reported together, but are appropriate under the circumstances. documentation must support a different session, different procedure or surgery, different site or organ system, separate incision/excision, separate lesion, or separate injury (or area of injury in extensive injuries) not ordinarily encountered or performed on the same day by the same individual. however, when another already established modifier is appropriate it should be used rather than modifier 59. only if no more descriptive modifier is available, and the use of modifier 59 best explains the circumstances, should modifier 59 be used. note: modifier 59 should not be appended to an e/m service. to report a separate and distinct e/m service with a non-e/m service performed on the same date, see modifier 25. | 77 | Repeat procedure by another physician or other qualified health care professional: it may be necessary to indicate that a basic procedure or service was repeated by another physician or other qualified health care professional subsequent to the original procedure or service. this circumstance may be reported by adding modifier 77 to the repeated procedure or service. note: this modifier should not be appended to an e/m service. | GV | Attending physician not employed or paid under arrangement by the patient's hospice provider | GW | Service not related to the hospice patient's terminal condition | Q6 | Service furnished under a fee-for-time compensation arrangement by a substitute physician or by a substitute physical therapist furnishing outpatient physical therapy services in a health professional shortage area, a medically underserved area, or a rural area |
|
Date
|
Action
|
Notes
|
|---|---|---|
| Pre-1990 | Added | Code added. |
Get instant expert-level medical coding assistance.